 |
|
AIDS-Related Kaposi Sarcoma
The Role of Local Therapy for a Systemic Disease
Bruce J. Dezube, MD
Arch Dermatol. 2000;136:1554-1556.
|
|
| Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings. |
|
|
|
INTRODUCTION
Kaposi sarcoma (KS) is the most common tumor that occurs in patients infected with the human immunodeficiency virus (HIV) and is an acquired immunodeficiency syndrome (AIDS)–defining illness according to the guidelines of the Centers for Disease Control and Prevention (CDC). In the United States, KS is over 20,000 times more common in people with AIDS than in the general population and over 300 times more common than in other immunosuppressed patients such as renal transplant recipients.1 Although KS has been reported among all risk groups for HIV infection, it is more common in homosexual or bisexual men. As reported to the CDC, KS occurs in roughly 20% of HIV-infected homosexual men, a sharp contrast when compared with the occurrence of KS in 3% of heterosexual intravenous drug users, 3% of transfusion recipients, 3% of women or children, and 1% of hemophiliacs. It is important to stress . . . [Full Text of this Article]
PATHOGENESIS OF KS: DISCOVERY OF POTENTIAL TARGETS FOR KS THERAPIES
TREATMENT
Highly Active Antiretroviral Therapy Local Therapy Systemic Therapy
FUTURE DIRECTIONS
From the Harvard Medical School, Beth Israel Deaconess Medical Center, Boston, Mass.
RELATED ARTICLE
Topical Treatment of Cutaneous Lesions of Acquired Immunodeficiency Syndrome–Related Kaposi Sarcoma Using Alitretinoin Gel: Results of Phase 1 and 2 Trials
Madeleine Duvic, Alvin E. Friedman-Kien, David J. Looney, Steven A. Miles, Patricia L. Myskowski, David T. Scadden, Jamie Von Roenn, Jeffrey E. Galpin, Jerome Groopman, Gordon Loewen, Victor Stevens, Joseph A. Truglia, and Richard C. Yocum
Arch Dermatol. 2000;136(12):1461-1469.
ABSTRACT
| FULL TEXT
|
